Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 ACADIA PharmaceuticalsAscendis Pharma A/SUltragenyx PharmaceuticalIonis PharmaceuticalsUnited Therapeutics
SymbolNASDAQ:ACADNASDAQ:ASNDNASDAQ:RARENASDAQ:IONSNASDAQ:UTHR
Price Information
Current Price$21.50$124.94$107.77$42.08$211.93
52 Week RangeHoldBuyBuyHoldBuy
MarketRank™
Overall Score1.91.51.61.61.5
Analysis Score4.23.54.34.12.5
Community Score3.22.63.32.32.2
Dividend Score0.00.00.00.00.0
Ownership Score1.70.80.01.71.7
Earnings & Valuation Score0.60.60.60.01.3
Analyst Ratings
Consensus RecommendationHoldBuyBuyHoldBuy
Consensus Price Target$32.76$192.22$136.47$57.45$219.57
% Upside from Price Target52.39% upside53.85% upside26.63% upside36.54% upside3.61% upside
Trade Information
Market Cap$3.44 billion$6.72 billion$7.31 billion$5.84 billion$9.44 billion
Beta1.440.772.191.420.52
Average Volume2,195,594206,189447,9121,228,435385,703
Sales & Book Value
Annual Revenue$339.08 million$14.98 million$103.71 million$1.12 billion$1.45 billion
Price / Sales10.15448.3069.575.286.52
CashflowN/AN/AN/A$1.71 per shareN/A
Price / CashN/AN/AN/A24.55N/A
Book Value$4.54 per share$15.87 per share$11.32 per share$11.98 per share$63.36 per share
Price / Book4.747.879.523.513.34
Profitability
Net Income$-235,260,000.00$-244,180,000.00$-402,730,000.00$303.26 million$-104,500,000.00
EPS($1.60)($5.25)($7.36)$2.08($2.39)
Trailing P/E RatioN/AN/AN/A87.6720.05
Forward P/E RatioN/AN/AN/AN/A18.29
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-63.92%-4,042.79%-119.19%7.82%33.25%
Return on Equity (ROE)-40.35%-55.72%-50.69%6.57%15.48%
Return on Assets (ROA)-34.72%-49.42%-26.87%3.39%11.31%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/A0.51%0.24%
Current Ratio7.95%14.80%4.33%10.37%7.22%
Quick Ratio7.86%14.80%4.26%10.28%6.88%
Ownership Information
Institutional Ownership Percentage93.54%N/AN/A84.14%90.09%
Insider Ownership Percentage27.70%40.00%8.20%2.40%10.90%
Miscellaneous
Employees601482893757950
Shares Outstanding160.05 million53.75 million66.95 million140.86 million44.54 million
Next Earnings Date5/5/2021 (Confirmed)5/18/2021 (Estimated)5/5/2021 (Estimated)5/5/2021 (Confirmed)5/5/2021 (Estimated)
OptionableOptionableOptionableOptionableOptionableOptionable
SourceHeadline
Pre-earnings Momentum Trade With a Technical Trigger in United Therapeutics CorpPre-earnings Momentum Trade With a Technical Trigger in United Therapeutics Corp
cmlviz.com - April 21 at 6:35 PM
Wedbush Stick to Their Buy Rating for United TherapeuticsWedbush Stick to Their Buy Rating for United Therapeutics
investing.com - April 21 at 1:35 PM
United Therapeutics (NASDAQ:UTHR) Shares Gap Up to $203.84United Therapeutics (NASDAQ:UTHR) Shares Gap Up to $203.84
americanbankingnews.com - April 21 at 11:02 AM
United Therapeutics takes latest step in aggressive push to launch more productsUnited Therapeutics takes latest step in aggressive push to launch more products
bizjournals.com - April 19 at 1:59 PM
Mannkind and United Therapeutics Reach a Milestone in the Development of Tyvaso DPI™ With New Drug Application Submitted to the FDAMannkind and United Therapeutics Reach a Milestone in the Development of Tyvaso DPI™ With New Drug Application Submitted to the FDA
markets.businessinsider.com - April 19 at 8:56 AM
Mannkind and United Therapeutics Reach a Milestone in the Development of Tyvaso DPI(TM) With New Drug Application Submitted to the FDAMannkind and United Therapeutics Reach a Milestone in the Development of Tyvaso DPI(TM) With New Drug Application Submitted to the FDA
marketwatch.com - April 19 at 8:56 AM
Mannkind and United Therapeutics Reach a Milestone in the Development of Tyvaso DPI™ With New ...Mannkind and United Therapeutics Reach a Milestone in the Development of Tyvaso DPI™ With New ...
apnews.com - April 19 at 8:56 AM
United Therapeutics (NASDAQ:UTHR) Sets New 1-Year High at $205.52United Therapeutics (NASDAQ:UTHR) Sets New 1-Year High at $205.52
americanbankingnews.com - April 17 at 12:12 PM
United Therapeutics (NASDAQ:UTHR) Sets New 52-Week High on Analyst UpgradeUnited Therapeutics (NASDAQ:UTHR) Sets New 52-Week High on Analyst Upgrade
americanbankingnews.com - April 8 at 4:22 PM
United Therapeutics (NASDAQ:UTHR) Given New $212.00 Price Target at JPMorgan Chase & Co.United Therapeutics (NASDAQ:UTHR) Given New $212.00 Price Target at JPMorgan Chase & Co.
americanbankingnews.com - April 8 at 10:10 AM
JPMorgan Chase & Co. Boosts United Therapeutics (NASDAQ:UTHR) Price Target to $212.00JPMorgan Chase & Co. Boosts United Therapeutics (NASDAQ:UTHR) Price Target to $212.00
marketbeat.com - April 8 at 8:13 AM
Is UTHR Stock A Buy or Sell?Is UTHR Stock A Buy or Sell?
finance.yahoo.com - April 6 at 6:55 PM
United Therapeutics (UTHR) Gains on Tyvaso Label ExpansionUnited Therapeutics (UTHR) Gains on Tyvaso Label Expansion
finance.yahoo.com - April 5 at 12:53 PM
This Pharma Can Breathe New Life Into Your PortfolioThis Pharma Can Breathe New Life Into Your Portfolio
finance.yahoo.com - April 2 at 9:10 AM
United Therapeutics Receives FDA Approval For Tyvaso Therapy; Shares Pop 15%United Therapeutics Receives FDA Approval For Tyvaso Therapy; Shares Pop 15%
finance.yahoo.com - April 2 at 9:10 AM
United Therapeutics Target of Unusually High Options Trading (NASDAQ:UTHR)United Therapeutics Target of Unusually High Options Trading (NASDAQ:UTHR)
americanbankingnews.com - April 1 at 7:55 PM
United Therapeutics Shares Rise 15% as FDA Clears Pathway to Launch Tyvaso to Treat PH-ILDUnited Therapeutics Shares Rise 15% as FDA Clears Pathway to Launch Tyvaso to Treat PH-ILD
streetwisereports.com - April 1 at 6:53 PM
Wingstop, Guess rise; CarMax, Emergent BioSolutions fallWingstop, Guess rise; CarMax, Emergent BioSolutions fall
marketbeat.com - April 1 at 4:31 PM
United Therapeutics Jumps as FDA Clears Hypertension DrugUnited Therapeutics Jumps as FDA Clears Hypertension Drug
thestreet.com - April 1 at 1:52 PM
United Therapeutics (NASDAQ:UTHR) Hits New 12-Month High at $186.90United Therapeutics (NASDAQ:UTHR) Hits New 12-Month High at $186.90
americanbankingnews.com - April 1 at 10:40 AM
FDA approves inhaled pulmonary hypertension treatment from United TherapeuticsFDA approves inhaled pulmonary hypertension treatment from United Therapeutics
drugdeliverybusiness.com - April 1 at 8:50 AM
United Therapeutics: FDA Approves Tyvaso For PH-ILD - Quick FactsUnited Therapeutics: FDA Approves Tyvaso For PH-ILD - Quick Facts
nasdaq.com - April 1 at 8:50 AM
UTHR Aug 2021 160.000 putUTHR Aug 2021 160.000 put
ca.finance.yahoo.com - March 27 at 3:16 PM
UTHR May 2021 110.000 callUTHR May 2021 110.000 call
ca.finance.yahoo.com - March 27 at 9:52 AM
UTHR Aug 2021 200.000 putUTHR Aug 2021 200.000 put
ca.finance.yahoo.com - March 27 at 9:52 AM
Why Is United Therapeutics (UTHR) Down 0.3% Since Last Earnings Report?Why Is United Therapeutics (UTHR) Down 0.3% Since Last Earnings Report?
finance.yahoo.com - March 26 at 1:28 PM
UTHR May 2021 75.000 putUTHR May 2021 75.000 put
sg.finance.yahoo.com - March 18 at 9:28 AM
DateCompanyBrokerageAction
4/13/2021ACADIA PharmaceuticalsThe Goldman Sachs GroupReiterated Rating
4/13/2021ACADIA PharmaceuticalsJefferies Financial GroupReiterated Rating
4/13/2021ACADIA PharmaceuticalsMizuhoReiterated Rating
4/13/2021ACADIA PharmaceuticalsCanaccord GenuityReiterated Rating
4/13/2021ACADIA PharmaceuticalsMorgan StanleyLower Price Target
4/13/2021ACADIA PharmaceuticalsHC WainwrightReiterated Rating
4/6/2021ACADIA PharmaceuticalsSVB LeerinkLower Price Target
4/6/2021ACADIA PharmaceuticalsCantor FitzgeraldBoost Price Target
4/5/2021ACADIA PharmaceuticalsRaymond JamesDowngrade
4/5/2021ACADIA PharmaceuticalsNeedham & Company LLCLower Price Target
3/16/2021ACADIA PharmaceuticalsBank of AmericaReiterated Rating
3/15/2021ACADIA PharmaceuticalsCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellReiterated Rating
3/15/2021ACADIA PharmaceuticalsStifel NicolausReiterated Rating
3/15/2021ACADIA PharmaceuticalsGuggenheimReiterated Rating
3/30/2021Ascendis Pharma A/SOppenheimerDowngrade
3/17/2021Ascendis Pharma A/SCredit Suisse GroupLower Price Target
12/17/2020Ascendis Pharma A/SBerenberg BankInitiated Coverage
11/12/2020Ascendis Pharma A/SWells Fargo & CompanyBoost Price Target
9/30/2020Ascendis Pharma A/SWedbushBoost Price Target
9/14/2020Ascendis Pharma A/SJPMorgan Chase & Co.Initiated Coverage
5/20/2020Ascendis Pharma A/SCSFBBoost Price Target
2/12/2021Ultragenyx PharmaceuticalPiper SandlerBoost Price Target
2/12/2021Ultragenyx PharmaceuticalBarclaysBoost Price Target
1/11/2021Ultragenyx PharmaceuticalRobert W. BairdBoost Price Target
11/24/2020Ultragenyx PharmaceuticalEvercore ISIReiterated Rating
10/28/2020Ultragenyx PharmaceuticalTruistBoost Price Target
4/5/2021Ionis PharmaceuticalsUBS GroupReiterated Rating
3/29/2021Ionis PharmaceuticalsBMO Capital MarketsLower Price Target
3/23/2021Ionis PharmaceuticalsRoyal Bank of CanadaLower Price Target
12/15/2020Ionis PharmaceuticalsCowenUpgrade
1/20/2021United TherapeuticsLADENBURG THALM/SH SHBoost Price Target
(Data available from 4/22/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.